Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351

Cell competition between anaplastic thyroid cancer and normal thyroid follicular cells exerts reciprocal stress response defining tumor suppressive effects of normal epithelial tissue

Amrenova, A., Suzuki, K., Saenko, V., Yamashita, S., & Mitsutake, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249059 · Cited by 1

Molecular Diagnostics of Cancer [Working Title]

Piccaluga, P. P. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111118 · Cited by 1

Celecoxib enhances the response of tumor cells to cisplatin through upregulating PUMA in non–small cell lung cancer carrying wild-type p53

Xiao, Y., Wang, Z., Gu, M., Tan, J., & Li, W. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000026 · Cited by 1

Transcriptome analysis revealed the genes and major pathways involved in prunetrin treated hepatocellular carcinoma cells

Abusaliya, A., Kim, H. H., Vetrivel, P., Bhosale, P. B., Jeong, S. H., Park, M. Y., Lee, S. J., & Kim, G. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1400186 · Cited by 1

Evolved enzymes in the metabolism of biological poly-acids: Applications in otolaryngological biocatalysis

Li, S., Wang, W., Liu, S., Du, Y., & Zhao, N. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140068 · Cited by 1

Experimental kinetic mechanism of P53 condensation-amyloid aggregation

Borkosky, S. S., Peralta-Martinez, R., Armella-Sierra, A., Esperante, S., Lizárraga, L., García‐Pardo, J., Ventura, S., Sanchez, I. E., & Gay, G. D. P. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.04.009 · Cited by 1

TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

Zeng, W., Zhu, W., Yuan, G., Chen, J., Wang, Z., Hou, J., & Jiang, D. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04122-z · Cited by 2

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting

Al-Radi, O., Ingelshed, K., Eichhorn, L., Josefsson, H., Krkoška, M., Bräutigam, L., Lindström, S., Végvári, Á., Kheder, S., Cerrato, C. P., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08292-7 · Cited by 2

Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours

Rani, H., Subhadarshini, S., Jolly, M. K., & Mahadevan, V. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00646-x · Cited by 1

CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251–258 segment

Liu, Y., Liu, Y., Xu, C., Jiang, F., & Yang, X. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115474 · Cited by 1

A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer

Zeng, S., Deng, H., Dong, H., Huang, C., Ruan, R., Dai, X., Xiong, J., Deng, J., & Yao, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-04459-6 · Cited by 1

Artificial Intelligence-Enabled Integration Suggests TP53 Pathway Alterations as Prognostic Biomarkers in Populations with Disproportionate Health Burdens

Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031607 · Cited by 1

Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation

Maloney, M. F., Caushi, J. X., Cullen, L. A., Andrews, A. R., Ford, A. C., Gizzi, A. S., Souza, C., Stokes, K. L., Dobrev, V. S., Krapfl, K., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-1252 · Cited by 1

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS

Song, H., Chen, X., Xiao, S., Wu, J., Dai, Y., Wu, W., Wu, Y., 翁香勤, Song, J., Yan, N., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ads9325 · Cited by 1

Hereditary ovarian cancer

Котив, Х. Б., Городнова, Т. В., Соколенко, А. П., Берлев, И. В., & Имянитов, Е. Н. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-5-123-134 · Cited by 1

Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts

Shen, K., Hu, D., Zhang, Z., Guo, Y., Zhang, F., & Chen, S. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14030 · Cited by 1

Beta-D-glucan Polysaccharide Downregulates p53, and Prostate Specific Antigen Expression in Histological and Immunohistochemical study of Prostate Tumor Model

Fischera, C. E., & Agbor, C. A. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i4.23 · Cited by 1

The influence of a modified p53 C-terminal peptide by using a tumor-targeting sequence on cellular apoptosis and tumor treatment

Guo, X., Zhang, Y., Li, Q., Shi, F., HuangFu, Y., Li, J., & Lao, X. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01926-1 · Cited by 1

“The 10th International MDM2 Workshop”: Opening up new avenues for MDM2 and p53 research, the First International MDM2 Workshop in Asia

Ohki, R., Itahana, K., & Iwakuma, T. (2024) · Genes to Cells · doi:10.1111/gtc.13114 · Cited by 1

Regulatory role of protein p53 in the functional activity of the central nervous system

Kotov, V. N., Kostyaeva, M. G., Ibadullaeva, S. S., Ganshin, I. B., Ходорович, О. С., Valiev, T. T., & Kartasheva, A. F. (2024) · Morphology · doi:10.17816/morph.629463 · Cited by 1

Joint multi-omics screening of neutrophil-related biomarkers for lung adenocarcinoma

Li, Y., Fei, J., Yu, H., & Shen, W. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2024-0493 · Cited by 1

Research Progress on the Role of Zinc Finger Protein in Colorectal Cancer

Tang, Y., Zhao, J., Li, Z., Pan, C., Liu, J.-L., Zheng, K., Wang, X., & Zhang, Y. (2025) · Cancer Reports · doi:10.1002/cnr2.70123 · Cited by 1

TP53 gene mutation in lymphoepithelioma‑like carcinoma of the breast with thyroid cancer: A case report

Sun, J., Gao, J., Li­, ­., & Zhao, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14993 · Cited by 1

Specific TP53 mutations impair the recruitment of 53BP1 to DNA double-strand breaks underlying the mechanism of radioresistance

Fagherazzi, P., Stixová, L., & Bártová, E. (2025) · European Biophysics Journal · doi:10.1007/s00249-025-01774-8 · Cited by 1

Covalent Bifunctional Molecules (CBMs): Achievements and Challenges

Xin, Y., Chen, F., You, Q., Wang, L., & Zhang, Q. (2025) · Medicinal Research Reviews · doi:10.1002/med.70011 · Cited by 1

A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance

Douglass, D. P., Stine, K. C., & Farrar, J. E. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002115 · Cited by 1

Deep reinforcement learning for diagnosing various types of cancer by TP53 mutation patternsPreprint

Rahmani, A., Bidgoli, B. M., & Ahangaran, M. (2021) · Research Square · doi:10.21203/rs.3.rs-744748/v1 · Cited by 1

Editorial: The expanding network of p53 signaling: Reaching to the unknown of cancer

Zhou, X. Y., Jung, J. H., & Lu, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.978056 · Cited by 1

TP53 function over forms in multiple myeloma

Neri, P. E., & Boise, L. (2024) · Blood · doi:10.1182/blood.2023023487 · Cited by 1

Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’

Peuget, S., & Selivanova, G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00825-8 · Cited by 1

p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill

Manfredi, J. J. (2019) · The EMBO Journal · doi:10.15252/embj.2019103322

Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic SyndromesPreprint

Kanagal‐Shamanna, R., Bravo, G. M., Katsonis, P., Sasaki, K., Class, C. A., Benton, C. B., Jabbour, E. J., Chien, K. S., Luthra, R., Bueso-Ramos, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.08.194365

Transcriptomic Signature of Radiation Response in Li-Fraumeni Syndrome

Sauberli-Stewart, K. (2019) · TSpace (University of Toronto)

Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers

Kennaley, K. (2019) · Deep Blue (University of Michigan)

The oncogenic Runx3–Myc axis defines p53 -deficient osteosarcomagenesisPreprint

Otani, S., Date, Y., Ueno, T., Ito, T., Kajikawa, S., Omori, K., Taniuchi, I., Umeda, M., Komori, T., Toguchida, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442316

p53 supplementation as a targeted cancer gene therapy for glioblastoma

Sukumar, U. K., Massoud, T. F., & Paulmurugan, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00013-0

Neoadjuvant Therapy for Anaplastic Thyroid Carcinoma

Kansara, S., Cabanillas, M. E., & Zafereo, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-73951-5_5

Prognostic Value of Diverse TP53 Mutations in Metastatic Cancers: An Analysis of the Cbioportal DatabasePreprint

Liu, K., Yan, L., Wang, H., Jiao, X., Qin, B., Wu, Y., He, X., Duan, X.-P., Li, B., Zou, X. N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3910363

P53(Cp44), an Endogenous Human p53 Fragment Generated via M-Calpain-Mediated Cleavage Beyond Degradation

Albrecht, T., Chen, Z., Finnerty, C. C., & Boor, P. J. (2019) · Gastroenterology Pancreatology and Hepatobilary Disorders · doi:10.31579/2641-5194/023

西都原古墳群に埋置された「碑石」 : 西都原古墳群大正調査の基礎資料(1)

犬木, 努., & 近藤, 麻. (2013) · Institutional Repositories DataBase (IRDB) · doi:10.24484/sitereports.118079-42651

図解 避難生活を生き抜く うおつか流防災食 (特集 つくる・伝える 災害にそなえる食の知恵)

魚柄, 仁. (2008) · 食農教育

Molecular oncology in gynecologic cancer

Thaker, P. H., & Sood, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00036-x

Prognostic Signature of Pyroptosis-Related LncRNA Correlates with Clinical and Immunological Characteristics of Hepatocellular CarcinomaPreprint

Xiao, J., Yuan, W., Zhu, X., Yan, Y., Li, W., Wu, F., Mao, B., Zhang, J., Du, Y., Zhu, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2078140/v1

Deviating Alternative Splicing as a Molecular Subtype of Microsatellite Stable Colorectal Cancer

Strømme, J. M., Johannessen, B., & Skotheim, R. I. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00159

Data from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death

Choe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · doi:10.1158/2159-8290.c.6603190

Lung Adenocarcinoma Mutation Hotspot in Koreans: Oncogenic Mutation Potential of the TP53 P72R Single Nucleotide Polymorphism

Jae Ha, B. A. E. K., & Cho, K. B. (2023) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2023.55.2.93

Optimizing Allosteric Analysis: A Wasserstein Distance and Heat Kernel Based Methodology for Investigating p53 Energetics

Cowan, B. S. (2023) · doi:10.14418/wes01.2.395

Thermal Stimuli-Responsive Nanoplatform Based on Phase Change Material for Synergistic Enhancement of p53 Protein Expression in HCCPreprint

Xu, W., Zhang, T., Zhang, W., Jia, W., liu, S., Peng, H. F., Zhang, H., Yang, R., & Zhang, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3209111/v1

Advances in Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma

梁, 亚. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102187

Restoration of Tumor Suppression to Cancer Carrying p53 Mutations

Amin, M. N., & Liu, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003642

Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience

Poonsombudlert, K., Mott, S. L., Miller, B., Dhakal, P., Snow, A. N., Hornberg, S., Yodsuwan, R., Strouse, C. S., Shaikh, H. G., Magalhaes-Silverman, M. D., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14199

Additional file 1 of TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., Cheng, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24709035

Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR4

Hassan, B. (2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr4

Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR6

(2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr6

Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR2

(2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr2

Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR5

(2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr5

Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR3

(2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr3

Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR1

Hassan, B. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1.pr1

The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study

Cui, H., Li, H., Liu, J., Zhao, P., Liu, Y., Zhong, R., Li, R., & Cheng, Y. (2024) · Medicine · doi:10.1097/md.0000000000038574

Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report

Wessman, S., Mogensen, N., Ranta, S., Saft, L., Greenwood, T. V. B., Tesi, B., de Ståhl, T. D., & Baecklund, F. (2024) · Precision Oncogenomics · doi:10.1080/28354311.2024.2385849

Exploring the therapeutic potential of simvastatin in pancreatic neuroendocrine neoplasms: insights into cell cycle regulation and apoptosis

Shi, X., Yan, L., Lu, F., Ye, M., Yu, P., Zhong, Y., Chen, J., Hu, C.-H., & Tang, Q. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-363

Basic and Translational Science in Oncology

Bhatia, D. R., & Gupta, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_1

The Biological Behavior and Clinical Application Prospects of Deoxythymidine Kinase Gene in Tumors

Zheng, J., Wang, Q., Yan, L., Pan, Q., Chen, X., & Chen, Q. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241265396

T cell receptors, the molecular bodyguard in αβ T lymphocyte immunity

(2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99893-2.00009-9

A Unique Case of a Pediatric Patient with Six Childhood Cancers in Association with a Germline TP53 Gene Pathogenic Variant

Standing, S., Malkin, D. M., & Johnston, D. L. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31487

Resolving malignant cell heterogeneity from bulk tumor RNA-seq data with CDStatePreprint

Kraft, A., Yates, J., Barkmann, F., & Boeva, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.01.641017

Restoration of tumor suppressor protein with enhanced activity using super-tRNAs to induce tumor regressionPreprint

Kong, B., Zheng, Z., Mi, Z., Dou, Z., Yang, Y., Shen, Y., Dong, L., Lv, J., Li, Y., Liang, Q. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643282

TP53 ‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis

Chen, D., Cantu, M. D., Siddon, A. J., & Weinberg, O. K. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14421

Loss of tumour suppressor p53 rewires enhancer landscape and governs oncogenic progressionPreprint

Rani, H., Notani, D., & Mahadevan, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.28.667341

Integrative network toxicology and molecular docking reveal 4-Nonylphenol’s multifaceted mechanisms in breast cancer pathogenesis

Jia, C., & Fu, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331944

Artificial Intelligence Reveals Prognostic TP53 Pathway Alterations in FOLFOX-Treated Early-Onset Colorectal Cancer Among Populations at RiskPreprint

Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2025) · medRxiv · doi:10.1101/2025.10.27.25338923

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersPreprint

Alruwaili, M., Guo, Y., Zonneville, J., Melendy, T., Straubinger, R. M., Foster, B. A., Rajan, P., Withers, H. G., Chatley, S., Iyer, R. V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.687028

Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets

Liu, Y., Zheng, Z., Ni, M., Mao, S., Xiao, Y., Zhao, Y., Tian, B., Wang, L., Xu, H., & Hua, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08172-0

A set cover algorithm identifies minimal circulating tumour DNA sequencing targets for colorectal cancer detection

Moloney‐Geany, K., Black, M. A., Day, R. C., Guilford, P., & Dunnet, M. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-24719-9

Additional file 2 of Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours

Dhaka, B., & Sabarinathan, R. (2021) · Figshare · doi:10.6084/m9.figshare.14738658

Additional file 5 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930431

Additional file 2 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930422

Additional file 5 of TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648022

Additional file 6 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930434

Additional file 4 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930428

Additional file 3 of Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours

Dhaka, B., & Sabarinathan, R. (2021) · Figshare · doi:10.6084/m9.figshare.14738661

Additional file 2 of TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.24709141

Additional file 1 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930419

Additional file 3 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930425

Additional file 3 of TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648016

Additional file 7 of Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Figshare · doi:10.6084/m9.figshare.23930437

Additional file 4 of TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648019

La variante somática TP53 en América Latina: prevalencia, implicaciones funcionales y desafíos clínicos en oncología

Gracia, L. D. (2025) · Revista Multidisciplinar Epistemología de las Ciencias · doi:10.71112/06eh8813

Evaluation of miR-223-3p, FOXO1 and TP53 expression in patients with ovarian endometriosis

chelkasari, S. S., Mashayekhi, F., Zahiri, Z., & Salehi, Z. (2025) · Cell & Tissue Journal · doi:10.61882/jct.16.3.291

Hotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies

Zhang, R., Kou, W., Wu, T., & Zhou, R. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1712877

A prognostic signature derived from ac4C-associated genes stratifies survival and tumor immune microenvironment in cutaneous melanoma

Jin, Q., Jiang, N., Chen, G., Zhu, J., Niu, H., Han, Y., Li, C., Wang, S., & Liu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727135

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

Zhao, W., Hao, Q., Gan, Y., Tong, J., Chen, X., Tan, S., Ruan, R., Huang, Y., Cao, M., Deng, J., et al. (2026) · Advanced Science · doi:10.1002/advs.202513369

Primary pulmonary adenoid cystic carcinoma presenting with ground-glass opacity nodules coexisting with male breast adenoid cystic carcinoma: A case report

Wang, H., Peng, H., Zhang, L., Yan, X., & Lu, J. (2026) · Radiology Case Reports · doi:10.1016/j.radcr.2025.12.035

TP53 mutation is associated with improved disease control in patients with advanced RAS wild‐type colorectal adenocarcinoma treated with cetuximab and pembrolizumab

Fountzilas, C. K., Rosario, S. R., Witkiewicz, A. K., Withers, H. G., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Maguire, O., Minderman, H., Chatley, S., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70434

Radiogenomics of muscle-invasive bladder cancer: machine learning for predicting prognostically relevant genetic mutations

Wei, H., Fan, Z., Li, Y., Zheng, W., Zhang, X., Chen, Z., Li, W., Du, J., & Wang, X. (2026) · Chinese Journal of Academic Radiology · doi:10.1007/s42058-026-00223-5

Complications hématologiques du syndrome de Shwachman-Diamond : neutropénie et leucémie aiguë myéloïde

Martignoles, J. (2022) · theses.fr (ABES) · doi:10.70675/dc56799dzc2f9z460fz892az3a689bd2251a

Integrated immunogenomic analysis exploring tumor heterogeneity and evolution of hepatocellular carcinoma

Pan, L. (2024) · theses.fr (ABES) · doi:10.70675/821ba15dz5e53z43e6zbe54zf564001c002e

A Novel Glycolysis Evaluation System for Stratified Management and Individualized Treatment of OSCC PatientsPreprint

Tan, R., Ye, J. W., Xu, Z., & Tang, H. (2026) · Research Square · doi:10.21203/rs.3.rs-8687369/v1

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin ShreddingPreprint

Zeng, J., Cheng, Z., Chen, H., Thompson, J., Crosby, K. T., Hang, H., Ngo, W., Xia, C., Rosas-Rivera, D., Kang, M. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.08.723607

Pentacyclic triterpenoid-isothiocyanate derivatives target mutant p53 through dual mechanisms of reactivation and degradation

Zhang, L., Wang, R., Du, X., Wang, J., Geng, X., Jihong, Z., & Yu, F. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103533

Targeting mutant p53 for cancer therapy

Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 230

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29

Molecularly targeted therapies for p53-mutant cancers

Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 82